A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

This study is looking for adults aged 18 or older who have an advanced solid tumour. This means the cancer may have spread or cannot be removed by surgery. You would need to have already tried or not be able to have standard cancer treatments.\n\nYou would also need to be generally well enough to take part in all the study activities. Doctors will check various health markers, like blood test results and how active you are, to make sure it's safe for you. You would also need to agree to have a small tissue sample (biopsy) taken before and during the study.\n\nThere are specific medical checks the doctors will perform, including looking at your blood counts, kidney, and liver function. These checks are to ensure your body is healthy enough for the new medicines and to keep you safe throughout the study. Having a 'lesion' that doctors can measure is also important, so they can see if the treatment is having an effect.

If you join this study, you will receive two medicines, BI 1703880 and ezabenlimab, through a drip into a vein (infusion). For the first six weeks, you will get BI 1703880 once a week. After that, you'll receive BI 1703880 every three weeks. Ezabenlimab will be added to your treatment every three weeks starting from the fourth week.\n\nTreatment with BI 1703880 can last for up to one year, and ezabenlimab for up to two years, as long as the treatment seems to be helping you and you are not experiencing severe side effects. Throughout this time, you'll have regular visits to the study clinic. During these visits, the medical team will closely monitor your health, perform necessary tests, and record any side effects you might experience. They will also repeatedly check your cancer to see how it's responding to the treatment.